Ambrx Biopharma appoints Andrew Aromando as COO
- Ambrx Biopharma (NASDAQ:AMAM) has appointed Andrew P. Aromando as Chief Operating Officer to succeed Sonja Nelson who served as both Chief Financial Officer and Chief Operating Officer over the past several months.
- The addition of Andrew, will allow Sonja to again focus her talents exclusively on her role as our CFO.
- He will be responsible for leading certain operational functions, as well as the company’s business development activities.
- Mr. Aromando has served in C-level roles for 15 years across multiple oncology-focused biopharmaceutical companies.
- In connection with his appointment, Andrew Aromando received a one-time inducement award of 2.6M ordinary share options, or the equivalent of 371,428 American Depository Shares, which vest over 4 years.